Inhibrx Biosciences

INBX · NASDAQ

$95.30+$5.51 (+6.14%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $89.79

INBX analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $272.00 (+185.4% upside)

Low: $232.30
Now: $95.30
High: $341.25

Upgrades and downgrades

The latest rating actions, newest first

INBX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Aug 24, 2026	Initiates	Buy	$245.00	41%
Stifel	Apr 8, 2026	Initiates	Buy	$150.00	43%

The case for and against

Updated Sep 23, 2026

Bull case

Inhibrx Biosciences is a promising biopharmaceutical company with strong potential for success through their innovative multivalent therapy, INBRX-106, and their diverse pipeline targeting various diseases such as head and neck cancers, AATD, and chondrosarcoma. The company has shown promising results and plans to submit a BLA for ozekibart in the near future with potential for use in combination with other drugs to enhance effectiveness. Despite some concerns about liver toxicity, Inhibrx Biosciences is expected to make a successful transition to a commercial-stage in the coming year and may stand out in a competitive market through the use of their Combo technology.

Bear case

Inhibrx Biosciences is currently facing several challenges, including competition from larger biopharmaceutical companies with more resources, potential patent infringement lawsuits, and the ongoing controversy surrounding drug pricing in the U.S. The company's pipeline is predominantly focused on agonists, which have historically shown limited clinical success due to issues such as toxicity and the need for secondary cross-linking. In addition, their lead candidate, INBRX-109, has shown modest results in its clinical trials and may face difficulty in achieving significant market penetration. These factors, combined with uncertainty surrounding the drug pricing environment and the company's financial position, lead to a negative outlook on the stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.